59 related articles for article (PubMed ID: 38555374)
21. Epigenetic Upregulation of MAGE-A Isoforms Promotes Breast Cancer Cell Aggressiveness.
Oh C; Kim HR; Oh S; Ko JY; Kim Y; Kang K; Yang Y; Kim J; Park JH; Roe JS; Yoo KH
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34202157
[TBL] [Abstract][Full Text] [Related]
22. A novel era of cancer/testis antigen in cancer immunotherapy.
Meng X; Sun X; Liu Z; He Y
Int Immunopharmacol; 2021 Sep; 98():107889. PubMed ID: 34174699
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
Yang P; Meng M; Zhou Q
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
[TBL] [Abstract][Full Text] [Related]
24. A review of digital cytometry methods: estimating the relative abundance of cell types in a bulk of cells.
Le T; Aronow RA; Kirshtein A; Shahriyari L
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33003193
[TBL] [Abstract][Full Text] [Related]
25. The roles of
Tsang YH; Mills GB
Autophagy; 2020 Oct; 16(10):1923-1924. PubMed ID: 32809888
[TBL] [Abstract][Full Text] [Related]
26. The biology
Kalluri R; LeBleu VS
Science; 2020 Feb; 367(6478):. PubMed ID: 32029601
[TBL] [Abstract][Full Text] [Related]
27. MAGE-A expression in oral and laryngeal leukoplakia predicts malignant transformation.
Baran CA; Agaimy A; Wehrhan F; Weber M; Hille V; Brunner K; Wickenhauser C; Siebolts U; Nkenke E; Kesting M; Ries J
Mod Pathol; 2019 Jul; 32(8):1068-1081. PubMed ID: 30936424
[TBL] [Abstract][Full Text] [Related]
28. TISIDB: an integrated repository portal for tumor-immune system interactions.
Ru B; Wong CN; Tong Y; Zhong JY; Zhong SSW; Wu WC; Chu KC; Wong CY; Lau CY; Chen I; Chan NW; Zhang J
Bioinformatics; 2019 Oct; 35(20):4200-4202. PubMed ID: 30903160
[TBL] [Abstract][Full Text] [Related]
29. Exosomes in inflammation and role as biomarkers.
Console L; Scalise M; Indiveri C
Clin Chim Acta; 2019 Jan; 488():165-171. PubMed ID: 30419221
[TBL] [Abstract][Full Text] [Related]
30. Tissue and Blood Biomarkers in Lung Cancer: A Review.
Duffy MJ; O'Byrne K
Adv Clin Chem; 2018; 86():1-21. PubMed ID: 30144837
[TBL] [Abstract][Full Text] [Related]
31. The expression of the cancer testis antigen MAGE A4: A favorable prognostic biomarker in salivary gland carcinomas related to low tumor grading.
Vital D; Ikenberg K; Moch H; Roessle M; Huber GF
Laryngoscope Investig Otolaryngol; 2018 Jun; 3(3):182-190. PubMed ID: 30062133
[TBL] [Abstract][Full Text] [Related]
32. Antibody response against cancer-testis antigens MAGEA4 and MAGEA10 in patients with melanoma.
Õunap K; Kurg K; Võsa L; Maiväli Ü; Teras M; Planken A; Ustav M; Kurg R
Oncol Lett; 2018 Jul; 16(1):211-218. PubMed ID: 29928403
[TBL] [Abstract][Full Text] [Related]
33. MAGE-A antigens as targets for cancer immunotherapy.
Schooten E; Di Maggio A; van Bergen En Henegouwen PMP; Kijanka MM
Cancer Treat Rev; 2018 Jun; 67():54-62. PubMed ID: 29763778
[TBL] [Abstract][Full Text] [Related]
34. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.
Shukla SA; Bachireddy P; Schilling B; Galonska C; Zhan Q; Bango C; Langer R; Lee PC; Gusenleitner D; Keskin DB; Babadi M; Mohammad A; Gnirke A; Clement K; Cartun ZJ; Van Allen EM; Miao D; Huang Y; Snyder A; Merghoub T; Wolchok JD; Garraway LA; Meissner A; Weber JS; Hacohen N; Neuberg D; Potts PR; Murphy GF; Lian CG; Schadendorf D; Hodi FS; Wu CJ
Cell; 2018 Apr; 173(3):624-633.e8. PubMed ID: 29656892
[TBL] [Abstract][Full Text] [Related]
35. MAGE-A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer.
Gu L; Sang M; Yin D; Liu F; Wu Y; Liu S; Huang W; Shan B
Thorac Cancer; 2018 Apr; 9(4):431-438. PubMed ID: 29430849
[TBL] [Abstract][Full Text] [Related]
36. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells.
Li T; Fan J; Wang B; Traugh N; Chen Q; Liu JS; Li B; Liu XS
Cancer Res; 2017 Nov; 77(21):e108-e110. PubMed ID: 29092952
[TBL] [Abstract][Full Text] [Related]
37. Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer.
Chen X; Wang L; Liu J; Huang L; Yang L; Gao Q; Shi X; Li J; Li F; Zhang Z; Zhao S; Zhang B; Van der Bruggen P; Zhang Y
Oncol Lett; 2017 Mar; 13(3):1609-1618. PubMed ID: 28454298
[TBL] [Abstract][Full Text] [Related]
38. MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma: a retrospective clinical study based on tissue microarray.
Sang M; Gu L; Yin D; Liu F; Lian Y; Zhang X; Liu S; Huang W; Wu Y; Shan B
J Clin Pathol; 2017 Jun; 70(6):533-540. PubMed ID: 27864450
[TBL] [Abstract][Full Text] [Related]
39. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.
Lánczky A; Nagy Á; Bottai G; Munkácsy G; Szabó A; Santarpia L; Győrffy B
Breast Cancer Res Treat; 2016 Dec; 160(3):439-446. PubMed ID: 27744485
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
